Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 161

The DOI matches its Crossref record.

Plasma osteopontin: Associations with survival and metastasis to bone in men with hormone‐refractory prostate carcinoma

Open access
Hotte, Sebastien J., Winquist, Eric W., Stitt, Larry, Wilson, Sylvia M., Chambers, Ann F. · 2002 · Cancer

Abstract

BACKGROUND: Osteopontin (OPN) is a secreted glycoprotein that is detectable in human body fluids. Its increased expression has been found in many malignancies, and a stimulatory effect on human prostate carcinoma cells in vitro has been demonstrated. Plasma OPN levels have been associated with tumor burden and survival in patients with metastatic breast carcinoma. The authors explored these associations in men with hormone‐refractory prostate carcinoma (HRPC). METHODS: Plasma samples from 100 men with HRPC were collected. OPN was measured using an antigen‐capture enzyme‐linked immunosorbent assay technique. Multivariable analyses were performed to identify predictors of OPN and survival. RESULTS: At the time of OPN sampling, the median patient age was 73 years (range, 50–86 years), and 92% of patients had metastases. The median plasma OPN level was 198.5 ng/mL (range, 15.0–2363.0 ng/mL), the median prostate specific antigen level was 67.8 μg/L (range, 0.1–7550.0 μg/L), and the median survival was 13.7 months. OPN plasma levels were higher in patients with versus patients without bone metastases (P = 0.024). Multivariable modeling demonstrated an independent association of the OPN level with alkaline phosphatase, hemoglobin, and creatinine levels. The log‐transformed OPN level (hazard ratio [HR], 2.38; P < 0.0001), performance status (HR, 2.43; P = 0.007), and a history of prior radiotherapy for localized prostate carcinoma (HR, 0.48; P = 0.0229) were independent predictors of survival in a Cox multivariate model. CONCLUSIONS: In this study, in men with established HRPC, the plasma OPN level was associated with the presence of metastases to bone and with other measures of tumor burden, and it was correlated independently and negatively with survival. Cancer 2002;95:506–12. © 2002 American Cancer Society. DOI 10.1002/cncr.10709

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.10709

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 161

Metadata

Authors
Hotte, S. J., Winquist, E. W., Stitt, L., Wilson, S. M., & Chambers, A. F.
Venue
Cancer
Publisher
Wiley
Published
2002-07-23
Volume
95
Issue
3
Pages
506-512
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2012195608
Cited by
161
References
0
FWCI
6.47
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Plasma osteopontin: Associations with survival and metastasis to bone in men with hormone‐refractory prostate carcinoma. https://app.cochat.ai/papers/10.1002/cncr.10709
The paper
Hotte, S. J., Winquist, E. W., Stitt, L., Wilson, S. M., & Chambers, A. F. (2002). Plasma osteopontin: Associations with survival and metastasis to bone in men with hormone‐refractory prostate carcinoma. Cancer. https://doi.org/10.1002/cncr.10709

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.